NCT04297020
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 35 Years to 65 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be undergoing endocrine therapy
Exclusions: 
https://ClinicalTrials.gov/show/NCT04297020